Hepatology

Clinical evidence, research, and medical intelligence in Hepatology.

MASLD Therapies Move Toward Fibrosis-Guided Clinical Care

New MASLD therapies and fibrosis-based pathways are reshaping care as incretins, THR-β agonists, and FGF analogs show disease-modifying effects.

By Dr. A. Nikhil Krishnan, MBBS · Oct 26, 2026 · 5 min read

Hepatology·Cancer Cell

Bile Acids Emerge as Hormone-Like Drivers of Aging-Related Liver Disease

Aging alters bile acid signaling, linking FXR and TGR5 pathways to liver senescence, inflammation, and disease across multiple…

Oct 26, 2026

Hepatology·Med News Today

Coffee Intake Linked With Lower Cirrhosis and Liver Cancer Risk

A large U.K. Biobank analysis linked higher coffee intake with lower cirrhosis and liver cancer risk over 13…

Oct 26, 2026

Hepatology·Gut

Carboxyl Fullerene Nanoparticle Targets Lipid Droplets in MASLD

A carboxyl fullerene derivative promoted PLIN2 degradation and blocked MASLD in preclinical models, offering a new lipid droplet-targeted…

Oct 25, 2026

Hepatology·Gut

IQILS accreditation drives hepatology service transformation in district hospital

A district general hospital reports a two-year hepatology quality improvement journey centered on IQILS accreditation and whole-system service…

Oct 25, 2026

Hepatology·BMJ

Built Environment and Liver Disease Burden in Plymouth Geospatial Study

A Plymouth geospatial analysis examines how community assets and the built environment may relate to liver disease burden…

Oct 25, 2026

Hepatology·J Hepatology

IL-22 Hepatocyte Expansion Raises Safety and Translation Questions

Journal of Hepatology abstract examines whether IL-22-driven long-term hepatocyte expansion can move safely from experimental biology toward clinical…

Oct 24, 2026

Hepatology·Gut

Circulating HBV RNA tracks cccDNA activity in chronic hepatitis B

Circulating HBV RNA closely reflected intrahepatic cccDNA activity in chronic hepatitis B and may help identify patients with…

Oct 24, 2026

Hepatology·EHJ

SR-B1 Transport Nanocarrier Improves Fibrosis Delivery in MASH

A simvastatin liposomal nanocarrier used SR-B1-mediated transport to cross capillarized liver sinusoids and improve antifibrotic delivery in MASH…

Oct 24, 2026

Hepatology·ClinicalTrials

Kylo-0603 Phase 2a Trial Targets MASLD Liver Fat Reduction

A Phase 2a study will test once-daily Kylo-0603 in MASLD, with MRI-PDFF liver fat change at 12 weeks…

Oct 24, 2026

Hepatology

Clinical evidence, research, and medical intelligence in Hepatology.

In Brief The 5-minute rounds

New hypertension guideline lowers the treatment threshold to 130/80 mm Hg.
Phase 3 GLP-1 trial reports a 20% cut in major adverse cardiac events.
FDA clears a next-generation CAR-T therapy for relapsed lymphoma.
Meta-analysis links early mobilisation to shorter ICU length of stay.
Rapid guidance broadens empiric antibiotics for suspected sepsis.